Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy

Table 1 Patient characteristics of the entire cohort

Characteristics	No. of patients (N = 721)	%
Breast cancer type
Invasive ductal	664	92
Invasive lobular	9	1
Mixed ductal/lobular	14	2
Breast cancer, NOS^a	16	2
Other	18	3
Age, years
21–40	154	21
41–60	449	63
> 60	118	16
Race
White	423	59
Hispanic	136	19
Black	109	15
Asian	45	6
Other	8	1
Menopausal status
Unknown	1	0
Premenopausal	314	44
Pregnant	3	0
Perimenopausal	14	2
Postmenopausal	389	54
Clinical stage
IIA	292	41
IIB	153	21
IIIA	78	11
IIIB	66	9
IIIC	132	19
Estrogen receptor status
Unknown	15	2
Negative	454	63
Positive	252	35
Progesterone receptor status
Unknown	19	3
Negative	526	73
Positive	176	24
HER2 status
Negative	286	40
Positive	312	43
Equivocal	123	17
Tumor subtype
Unknown	18	3
HR	157	22
TN	236	33
HER2-amplified	310	43
HR+	128	41
HR−	178	57
Unknown HR	4	1
Neoadjuvant chemotherapy
A no T	56	8
A + T	367	51
AT + HER2	227	31
PC	71	10
HER2+ patient regimens
HER2-containing regimen	247	80
No HER2	60	20
Length of NACT therapy
0–4 months	64	9
4 & 7 months	570	79
7 months	87	12
Neoadjuvant hormonal therapy
Yes	12	0
No	715	100
Neoadjuvant radiation therapy
Yes	1	0
No	720	100
Adjuvant chemotherapy
Yes	196	27
No	525	73
Adjuvant endocrine therapy
Yes	261	36
No	460	64
Adjuvant radiation therapy
Yes	559	78
No	162	22
Outcomes
Progression	63	9
Death (any cause)	62	9
Progression + death	40	6
Death without progression	22	3
Site of metastasis
Distant first	41	65
Brain-only	13	32
Bone-only	4	10
Liver-only	4	10
Lung-only	3	7
Mixed/other	17	41
Local first	11	17
Chest wall-only	1	9
Ipsilateral breast-only	10	91
Both local and distant	11	17
Concurrent^a	6	55
Sequential	5	45

Abbreviations: NOS Not otherwise specified, HR Hormone receptor; TN Triple-negative breast cancer, A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC Provider choice, NACT Neoadjuvant chemotherapy
^aConcurrent local and distant metastases were diagnosed within 1 month of each other

ISSN: 1465-542X